MarketCap
Facebook
X
Telegram
BioVie EV - Enterprise Value | BIVI
Annual EV - Enterprise Value BioVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.6 M | -13.6 M | 11.9 M | 57 M | 33.7 M | 90.1 M | 31.8 M | 21.2 M | 18.7 M | 11.1 M | 15.8 M | 17.2 M | -491 K | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 90.1 M | -13.6 M | 21.7 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
104 M | $ 0.69 | 11.43 % | $ 73.6 M | Britain |
 |
MorphoSys AG
MOR
|
2.44 B | - | 2.43 % | $ 254 M |  Germany |
 |
Affimed N.V.
AFMD
|
-38.5 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
215 M | - | -1.58 % | $ 28.1 M |  China |
 |
Celyad Oncology SA
CYAD
|
-1.83 M | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
-10.5 M | $ 1.63 | 0.18 % | $ 90.4 M |  USA |
 |
Gracell Biotechnologies
GRCL
|
-1.17 B | - | - | $ 3.37 B | China |
 |
Stoke Therapeutics
STOK
|
1.99 B | $ 26.51 | 1.69 % | $ 1.57 B | USA |
 |
Sutro Biopharma
STRO
|
429 M | $ 9.57 | 4.08 % | $ 81.3 M | USA |
 |
Silence Therapeutics plc
SLN
|
812 M | $ 19.73 | 0.03 % | $ 2.8 B | Britain |
 |
Taysha Gene Therapies
TSHA
|
1.23 B | $ 4.34 | 6.11 % | $ 1.39 B | USA |
 |
Soligenix
SNGX
|
2.13 M | $ 0.34 | 0.54 % | $ 1.76 M | USA |
 |
Spruce Biosciences
SPRB
|
9.21 M | $ 46.46 | 8.78 % | $ 35.6 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
3.38 B | $ 26.14 | -2.24 % | $ 1.48 B | USA |
 |
Galapagos NV
GLPG
|
1.99 B | - | - | $ 1.83 B | Belgium |
 |
Savara
SVRA
|
1.18 B | $ 4.82 | 9.93 % | $ 1.07 B | USA |
 |
Viking Therapeutics
VKTX
|
3.09 B | $ 26.86 | 4.15 % | $ 3.03 B | USA |
 |
Teligent, Inc.
TLGT
|
4.75 B | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
5.37 B | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
4.67 B | $ 59.78 | 3.1 % | $ 8.63 B | USA |
 |
Aphria Inc.
APHA
|
54.3 B | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
3.74 B | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
19.2 B | - | -6.00 % | $ 238 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
2.11 B | $ 3.37 | 4.66 % | $ 568 M |  Singapore |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
-10.8 M | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
1.09 B | - | 0.38 % | $ 12.9 M |  Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
864 M | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
2.9 B | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
-2.87 M | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
1.5 B | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
80.3 M | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
-14.6 M | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
33.2 M | - | - | $ 6.81 B | Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
27.5 B | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
-22.9 M | - | - | $ 256 M | Canada |
 |
argenx SE
ARGX
|
40.2 B | $ 928.5 | 3.77 % | $ 56.9 B |  Niderland |
|
XBiotech
XBIT
|
-45.4 M | $ 1.88 | 0.53 % | $ 57.3 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
-14.1 M | - | -2.54 % | $ 57.2 M | USA |
 |
Xencor
XNCR
|
1.08 B | $ 36.19 | 6.28 % | $ 2.69 B | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
5.24 B | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
284 M | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
6.61 B | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
29.5 K | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
-2.54 M | $ 1.87 | 0.31 % | $ 3.18 M | USA |
 |
Translate Bio, Inc.
TBIO
|
1.43 B | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
83.6 M | - | - | $ 1.94 B | Canada |
 |
Exicure
XCUR
|
35.4 M | $ 0.91 | 2.77 % | $ 5.73 M | USA |
 |
Urovant Sciences Ltd.
UROV
|
37.4 B | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-182 M | - | - | $ 10.9 B | USA |